JP Morgan, Jefferies: Advisory on $3.6bn Canadian Banking Acquisition Explained
JP Morgan and Jefferies advised NBC on acquiring CWB for $3.6bn, enhancing Canadian banking services and growth.
Barclays: Joint Bookrunner on £7bn Rights Issue by National Grid
Barclays and J.P. Morgan have successfully managed a £7 billion rights issue for National Grid PLC.
PGIM: New $500bn Private Markets AUM Strategy Explained
PGIM aims to expand its private-market assets to $500 billion within five years, representing a more than 50% increase.
Citi: Introducing the New Global Wealth Head Kris Bitterly
Citi has appointed Kris Bitterly as the new head of Wealth at Work, a significant division within the company.
Evercore: Exclusive Advisory on €500m PLG Continuation Fund
Evercore served as the sole financial advisor to 21 Invest France on the €500m co-control sale and continuation fund transaction for ProductLife Group (PLG).
Perella Weinberg Partners: Advisory on Cognizant’s $1.3bn Acquisition of Belcan
Perella Weinberg Partners (PWP) and Jefferies served as financial advisors on Cognizant’s $1.3 billion acquisition of Belcan, a global provider of engineering and IT services.
Barclays: Advisory on Robinhood’s $200m Acquisition of Bitstamp Explained
Barclays Exclusive: Advisory on Robinhood’s Acquisition of Bitstamp for $200m
KKR Exclusive: EUR 438m Acquisition of FiberCop Stake Explained
KKR has agreed to acquire a 4.5% stake in FiberCop from Fastweb, a subsidiary of Swisscom, for EUR 438.7 million.
KKR: Record $871M Labrador Island Acquisition Explained
KKR has agreed to acquire a minority stake in the Labrador Island Link (LIL), an HVdc transmission system, from Emera for $871 million.
Blackstone: New $1.9bn Potential Sale of Alinamin Explained
Blackstone Inc. is considering selling Alinamin Pharmaceutical Co., a Japanese consumer healthcare firm previously owned by Takeda Pharmaceutical Co., according to individuals familiar with the matter. The world’s largest alternative asset manager, Blackstone, is working with financial advisers on the potential sale of Tokyo-based Alinamin, which could be valued at around ¥300 billion ($1.9 billion). […]